Author:
Amarikwa Linus,Michalak Suzanne M.,Caul Susan,Mruthyunjaya Prithvi,Rahimy Ehsan
Abstract
Vuity (pilocarpine HCL ophthalmic 1.25%) was approved for the treatment of presbyopia in October 2021. Previous case series have reported the presence of vitreofoveal traction and retinal detachment following pilocarpine administration, but this was not reported in the recent randomized control trials assessing the efficacy of Vuity. The authors report a case of a woman of 65 years who developed vitreomacular traction immediately following the first administration of Vuity, review the literature, and present considerations regarding screening and management of patients starting Vuity.
[
Ophthalmic Surg Lasers Imaging Retina
2022; 53:410–411.]
Reference6 articles.
1. Safety and Efficacy of AGN-190584 in Individuals With Presbyopia
2. Clinicaltrials.gov. A phase 3 efficacy study of pilocarpine HCl ophthalmic solution (AGN-190584) in participants with presbyopia (GEMINI 2). Available online: https://clinicaltrials.gov/ct2/show/results/NCT03857542?term=agn-190584&cond=Presbyopia&draw=2&rank=5 (accessed on 30 March 2022).
3. Retinal Detachment and Miotic Therapy
4. Vitreofoveal traction associated with the use of pilocarpine to reverse mydriasis
5. Miotics and retinal detachment: Upgrading the community standard
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献